{"id":"W4283797772","doi":"10.1016/j.msard.2022.104031","title":"Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis","year":2022,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"EVERSANA (Canada)","funders":"University of Bristol; Novartis Animal Health; Novartis","keywords":"Ocrelizumab; Medicine; Relapsing remitting; Ofatumumab; Multiple sclerosis; Internal medicine; Filgrastim; Oncology; Physical therapy; Dermatology; Rituximab; Immunology; Granulocyte colony-stimulating factor; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007090431,0.0009495197,0.002521758,0.0003678779,0.0002400674,0.0009294261,0.00086559,0.001232552,0.005165172],"category_scores_gemma":[0.01970277,0.0004250527,0.00339724,0.000298994,0.0008565456,0.0008691604,0.0007144902,0.001944447,0.0003872481],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001553697,"about_ca_system_score_gemma":0.00178113,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002669607,"about_ca_topic_score_gemma":0.001086486,"domain_scores_codex":[0.9956505,0.003127642,0.0002138197,0.0003955794,0.0001999778,0.0004125321],"domain_scores_gemma":[0.9803001,0.0151157,0.002046145,0.000944932,0.0006029235,0.0009902888],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.8586626,0.007656523,0.004022156,0.0006047292,0.0032918,0.00007883731,0.0001008286,0.1022194,0.001329974,0.001595177,0.001623084,0.01881495],"study_design_scores_gemma":[0.3096862,0.3889095,0.0233935,0.0003483245,0.008918109,0.000175935,0.0002057283,0.2549289,0.004750893,0.005599922,0.002901955,0.0001811327],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932485,0.00102449,0.001531661,0.0002940586,0.0002342477,0.0005512305,0.001183313,0.00004214342,0.001890442],"genre_scores_gemma":[0.997403,0.0001514231,0.0006609191,0.0001146317,0.00005889151,0.0004624637,0.0007491448,0.000005563442,0.0003940653],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007090431,"threshold_uncertainty_score":0.03749824,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07481059588906752,"score_gpt":0.3151139462203904,"score_spread":0.2403033503313229,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}